Louis J. Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Louis J. Taylor has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Frederic D. Bushman
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
11 shared publications - Matthew B. Frieman
Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA
5 shared publications - Ronald G. Collman
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania
5 shared publications Lauren Baracco
Department of Microbiology and Immunology, Center for Pathogen Research, University of Maryland School of Medicine, Baltimore, Maryland, USA
4 shared publications- Arwa Abbas
Children’s Hospital of Philadelphia, Philadelphia, USA
3 shared publications Ayannah S. Fitzgerald
Pulmonary, Allergy and Critical Care Division, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
3 shared publications
Latest Publications
- Open Access
- 23 October 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (10) , e0132325
The mammalian SKI complex is a broad-spectrum antiviral drug target that upregulates cellular cholesterol to inhibit viral replication
There is a need for the development of broad-spectrum antiviral compounds that can act as first-line therapeutic countermeasures to emerging viral infections. Host-directed approaches present a promising avenue of development and carry the benefit of mitigating risks of viral escape mutants. We have previously found the SKI (super killer) complex to be a broad-spectrum, host-target with our lead compound ("UMB18") showing activity against influenza A virus, coronaviruses, and filoviruses. The SKI complex is a cytosolic RNA helicase, and we previously found that UMB18 inhibited viral RNA production but did not further define the mechanism. Here, we demonstrate that UMB18 directly binds to SKIC8 of the SKI complex, and transcriptomic analysis of UMB18-treated A549 cells revealed an upregulation of genes in the mevalonate pathway, which drives cholesterol synthesis. Further investigation validated the genetic upregulation and confirmed an increase in total cellular cholesterol. This upregulation was dependent on the sterol regulatory element-binding proteins (SREBPs) and their regulator SCAP, the major regulators for cholesterol and fatty acid synthesis. Depletion of the SREBPs or SCAP with siRNA, or extraction of cholesterol with methyl β-cyclodextrin, attenuated UMB18 antiviral activity, emphasizing the role of increased cholesterol synthesis in this mechanism of action. Our findings further define the antiviral mechanism of a developmental host-directed therapeutic approach with broad applicability against emerging viral pathogens. IMPORTANCE: The COVID-19 pandemic has underscored the need for effective countermeasures to emerging pathogens. Our research builds upon our published data on a novel antiviral compound termed UMB18. We have found UMB18 capable of inhibiting replication of influenza A virus, coronaviruses, and the filoviruses Marburg and Ebola virus, but did not fully define a mechanism of action. Here, we demonstrate that UMB18 exerts antiviral activity by modulating cellular cholesterol levels. By targeting the SKI complex, UMB18 triggers an increase in endogenous cellular cholesterol, which disrupts the fine balance that viruses rely on for efficient infection. We demonstrate that this mechanism inhibits replication of SARS-CoV-2, revealing a previously undescribed host-directed strategy for antiviral intervention. These findings highlight UMB18's potential as a broad-spectrum antiviral agent and pave the way for further research into its mechanism and therapeutic applications, offering a promising avenue for development of antiviral countermeasures to current, novel, and emerging pathogens.
- 23 October 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (10) , e0132325
Open AccessThe mammalian SKI complex is a broad-spectrum antiviral drug target that upregulates cellular cholesterol to inhibit viral replication
There is a need for the development of broad-spectrum antiviral compounds that can act as first-line therapeutic countermeasures to emerging viral infections. Host-directed approaches present a promising avenue of development and carry the benefit of mitigating risks of viral escape mutants. We have previously found the SKI (super killer) complex to be a broad-spectrum, host-target with our lead compound ("UMB18") showing activity against influenza A virus, coronaviruses, and filoviruses. The SKI complex is a cytosolic RNA helicase, and we previously found that UMB18 inhibited viral RNA production but did not further define the mechanism. Here, we demonstrate that UMB18 directly binds to SKIC8 of the SKI complex, and transcriptomic analysis of UMB18-treated A549 cells revealed an upregulation of genes in the mevalonate pathway, which drives cholesterol synthesis. Further investigation validated the genetic upregulation and confirmed an increase in total cellular cholesterol. This upregulation was dependent on the sterol regulatory element-binding proteins (SREBPs) and their regulator SCAP, the major regulators for cholesterol and fatty acid synthesis. Depletion of the SREBPs or SCAP with siRNA, or extraction of cholesterol with methyl β-cyclodextrin, attenuated UMB18 antiviral activity, emphasizing the role of increased cholesterol synthesis in this mechanism of action. Our findings further define the antiviral mechanism of a developmental host-directed therapeutic approach with broad applicability against emerging viral pathogens. IMPORTANCE: The COVID-19 pandemic has underscored the need for effective countermeasures to emerging pathogens. Our research builds upon our published data on a novel antiviral compound termed UMB18. We have found UMB18 capable of inhibiting replication of influenza A virus, coronaviruses, and the filoviruses Marburg and Ebola virus, but did not fully define a mechanism of action. Here, we demonstrate that UMB18 exerts antiviral activity by modulating cellular cholesterol levels. By targeting the SKI complex, UMB18 triggers an increase in endogenous cellular cholesterol, which disrupts the fine balance that viruses rely on for efficient infection. We demonstrate that this mechanism inhibits replication of SARS-CoV-2, revealing a previously undescribed host-directed strategy for antiviral intervention. These findings highlight UMB18's potential as a broad-spectrum antiviral agent and pave the way for further research into its mechanism and therapeutic applications, offering a promising avenue for development of antiviral countermeasures to current, novel, and emerging pathogens.
- Open Access
- 23 September 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (9) , e0111225
Discovery, phylogenetic, and comparative genomic analysis of novel avian gammacoronaviruses identified in feral pigeons ( Columba livia domestica )
The COVID-19 pandemic caused by SARS-CoV-2 has intensified efforts to identify emerging coronaviruses (CoVs) across diverse hosts. Spillover events, where CoVs transition from wildlife reservoirs to other species, can lead to infections with varying clinical outcomes, emphasizing the need for continued surveillance. Understanding the diversity and distribution of both known and novel CoVs in wildlife reservoirs is crucial for predicting and preventing future spillover events. In this study, we employed Illumina’s Pan-CoV library panel and next-generation sequencing (NGS) to identify five novel avian-associated gammacoronavirus genomes from cloacal and oropharyngeal swabs of clinically healthy feral pigeons captured in Durban, KwaZulu-Natal Province, South Africa, in 2018. The genome sequences, ranging from 27,582 to 27,611 nucleotides, clustered with gammacoronaviruses in phylogenetic analyses but formed a distinct clade. Comparative analysis of the five conserved domains in the ORF1ab coding sequence with other gammacoronaviruses revealed Pairwise Patristic Distances (PPD) that exceeded both species and subgenus demarcation cutoffs. These findings highlight the critical need for ongoing surveillance to enhance understanding of CoV diversity, host range, and potential for cross-species transmission, aligning with One Health principles. Based on these results, we propose Gammacoronavirus columbae as a new species for these pigeon gammacoronaviruses that clusters with the recently reported duck gammacoronaviruses to form a novel subgenus within Gammacoronavirus. IMPORTANCE: Although coronaviruses are significant pathogens affecting a wide range of hosts, surveillance efforts have predominantly focused on wild mammals, leaving the diversity of avian coronaviruses largely underexplored. Here, we report the detection of novel gammacoronaviruses from feral pigeons in South Africa and propose revisions to the current taxonomic classification of Gammacoronavirus based on genetic distance analyses. These findings highlight the potential role of wild birds in the dissemination of novel coronaviruses, analogous to their established involvement in the transmission of avian influenza viruses. Our study also highlights the utility of next-generation sequencing (NGS) technologies in uncovering the hidden diversity of viruses in wildlife populations. Finally, this study reinforces the need for ongoing surveillance, continued vigilance, and further research into avian coronaviruses. The ongoing highly pathogenic avian influenza (HPAI) outbreaks in the USA have demonstrated the devastating impact of emerging avian viruses on wildlife, agriculture, and public health. Given the unpredictability of coronavirus evolution, failing to monitor their diversity and potential for cross-species transmission risks leaving us unprepared for future outbreaks. This study reinforces the urgent need for proactive, large-scale genomic surveillance of wildlife reservoirs to identify emerging CoVs before they become significant threats to animal and human populations.
- 23 September 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (9) , e0111225
Open AccessDiscovery, phylogenetic, and comparative genomic analysis of novel avian gammacoronaviruses identified in feral pigeons ( Columba livia domestica )
The COVID-19 pandemic caused by SARS-CoV-2 has intensified efforts to identify emerging coronaviruses (CoVs) across diverse hosts. Spillover events, where CoVs transition from wildlife reservoirs to other species, can lead to infections with varying clinical outcomes, emphasizing the need for continued surveillance. Understanding the diversity and distribution of both known and novel CoVs in wildlife reservoirs is crucial for predicting and preventing future spillover events. In this study, we employed Illumina’s Pan-CoV library panel and next-generation sequencing (NGS) to identify five novel avian-associated gammacoronavirus genomes from cloacal and oropharyngeal swabs of clinically healthy feral pigeons captured in Durban, KwaZulu-Natal Province, South Africa, in 2018. The genome sequences, ranging from 27,582 to 27,611 nucleotides, clustered with gammacoronaviruses in phylogenetic analyses but formed a distinct clade. Comparative analysis of the five conserved domains in the ORF1ab coding sequence with other gammacoronaviruses revealed Pairwise Patristic Distances (PPD) that exceeded both species and subgenus demarcation cutoffs. These findings highlight the critical need for ongoing surveillance to enhance understanding of CoV diversity, host range, and potential for cross-species transmission, aligning with One Health principles. Based on these results, we propose Gammacoronavirus columbae as a new species for these pigeon gammacoronaviruses that clusters with the recently reported duck gammacoronaviruses to form a novel subgenus within Gammacoronavirus. IMPORTANCE: Although coronaviruses are significant pathogens affecting a wide range of hosts, surveillance efforts have predominantly focused on wild mammals, leaving the diversity of avian coronaviruses largely underexplored. Here, we report the detection of novel gammacoronaviruses from feral pigeons in South Africa and propose revisions to the current taxonomic classification of Gammacoronavirus based on genetic distance analyses. These findings highlight the potential role of wild birds in the dissemination of novel coronaviruses, analogous to their established involvement in the transmission of avian influenza viruses. Our study also highlights the utility of next-generation sequencing (NGS) technologies in uncovering the hidden diversity of viruses in wildlife populations. Finally, this study reinforces the need for ongoing surveillance, continued vigilance, and further research into avian coronaviruses. The ongoing highly pathogenic avian influenza (HPAI) outbreaks in the USA have demonstrated the devastating impact of emerging avian viruses on wildlife, agriculture, and public health. Given the unpredictability of coronavirus evolution, failing to monitor their diversity and potential for cross-species transmission risks leaving us unprepared for future outbreaks. This study reinforces the urgent need for proactive, large-scale genomic surveillance of wildlife reservoirs to identify emerging CoVs before they become significant threats to animal and human populations.
- Open Access
- 23 May 2024
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 20 (5) , e1011669
SARS-CoV-2 ORF8 modulates lung inflammation and clinical disease progression
The virus severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, is the causative agent of the current COVID-19 pandemic. It possesses a large 30 kilobase (kb) genome that encodes structural, non-structural, and accessory proteins. Although not necessary to cause disease, these accessory proteins are known to influence viral replication and pathogenesis. Through the synthesis of novel infectious clones of SARS-CoV-2 that lack one or more of the accessory proteins of the virus, we have found that one of these accessory proteins, ORF8, is critical for the modulation of the host inflammatory response. Mice infected with a SARS-CoV-2 virus lacking ORF8 exhibit increased weight loss and exacerbated macrophage infiltration into the lungs. Additionally, infection of mice with recombinant SARS-CoV-2 viruses encoding ORF8 mutations found in variants of concern reveal that naturally occurring mutations in this protein influence disease severity. Our studies with a virus lacking this ORF8 protein and viruses possessing naturally occurring point mutations in this protein demonstrate that this protein impacts pathogenesis.
- 23 May 2024
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 20 (5) , e1011669
Open AccessSARS-CoV-2 ORF8 modulates lung inflammation and clinical disease progression
The virus severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, is the causative agent of the current COVID-19 pandemic. It possesses a large 30 kilobase (kb) genome that encodes structural, non-structural, and accessory proteins. Although not necessary to cause disease, these accessory proteins are known to influence viral replication and pathogenesis. Through the synthesis of novel infectious clones of SARS-CoV-2 that lack one or more of the accessory proteins of the virus, we have found that one of these accessory proteins, ORF8, is critical for the modulation of the host inflammatory response. Mice infected with a SARS-CoV-2 virus lacking ORF8 exhibit increased weight loss and exacerbated macrophage infiltration into the lungs. Additionally, infection of mice with recombinant SARS-CoV-2 viruses encoding ORF8 mutations found in variants of concern reveal that naturally occurring mutations in this protein influence disease severity. Our studies with a virus lacking this ORF8 protein and viruses possessing naturally occurring point mutations in this protein demonstrate that this protein impacts pathogenesis.
- Open Access
- 28 February 2023
- Published by American Society for Microbiology in mBio
- Vol. 14 (1) , e0297322
HIV-1 Vpr Induces Degradation of Gelsolin, a Myeloid Cell-Specific Host Factor That Reduces Viral Infectivity by Inhibiting the Expression and Packaging of the HIV-1 Env Glycoprotein
Despite dramatic progress in drug therapies, HIV-1 infection remains an incurable disease that affects millions of people worldwide. The virus establishes long-lasting reservoirs that are resistant to currently available drug treatments and allow the virus to rebound whenever drug therapy is interrupted.
- 28 February 2023
- Published by American Society for Microbiology in mBio
- Vol. 14 (1) , e0297322
Open AccessHIV-1 Vpr Induces Degradation of Gelsolin, a Myeloid Cell-Specific Host Factor That Reduces Viral Infectivity by Inhibiting the Expression and Packaging of the HIV-1 Env Glycoprotein
Despite dramatic progress in drug therapies, HIV-1 infection remains an incurable disease that affects millions of people worldwide. The virus establishes long-lasting reservoirs that are resistant to currently available drug treatments and allow the virus to rebound whenever drug therapy is interrupted.
- Open Access
- 30 August 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (37)
SARS-CoV-2 variant spike and accessory gene mutations alter pathogenesis
The ongoing COVID-19 pandemic is a major public health crisis. Despite the development and deployment of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pandemic persists. The continued spread of the virus is largely driven by the emergence of viral variants, which can evade the current vaccines through mutations in the spike protein. Although these differences in spike are important in terms of transmission and vaccine responses, these variants possess mutations in the other parts of their genome that may also affect pathogenesis. Of particular interest to us are the mutations present in the accessory genes, which have been shown to contribute to pathogenesis in the host through interference with innate immune signaling, among other effects on host machinery. To examine the effects of accessory protein mutations and other nonspike mutations on SARS-CoV-2 pathogenesis, we synthesized both viruses possessing deletions in the accessory genes as well as viruses where the WA-1 spike is replaced by each variant spike gene in a SARS-CoV-2/WA-1 infectious clone. We then characterized the in vitro and in vivo replication of these viruses and compared them to both WA-1 and the full variant viruses. Our work has revealed that the accessory proteins contribute to SARS-CoV-2 pathogenesis and the nonspike mutations in variants can contribute to replication of SARS-CoV-2 and pathogenesis in the host. This work suggests that while spike mutations may enhance receptor binding and entry into cells, mutations in accessory proteins may alter clinical disease presentation.
- 30 August 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (37)
Open AccessSARS-CoV-2 variant spike and accessory gene mutations alter pathogenesis
The ongoing COVID-19 pandemic is a major public health crisis. Despite the development and deployment of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pandemic persists. The continued spread of the virus is largely driven by the emergence of viral variants, which can evade the current vaccines through mutations in the spike protein. Although these differences in spike are important in terms of transmission and vaccine responses, these variants possess mutations in the other parts of their genome that may also affect pathogenesis. Of particular interest to us are the mutations present in the accessory genes, which have been shown to contribute to pathogenesis in the host through interference with innate immune signaling, among other effects on host machinery. To examine the effects of accessory protein mutations and other nonspike mutations on SARS-CoV-2 pathogenesis, we synthesized both viruses possessing deletions in the accessory genes as well as viruses where the WA-1 spike is replaced by each variant spike gene in a SARS-CoV-2/WA-1 infectious clone. We then characterized the in vitro and in vivo replication of these viruses and compared them to both WA-1 and the full variant viruses. Our work has revealed that the accessory proteins contribute to SARS-CoV-2 pathogenesis and the nonspike mutations in variants can contribute to replication of SARS-CoV-2 and pathogenesis in the host. This work suggests that while spike mutations may enhance receptor binding and entry into cells, mutations in accessory proteins may alter clinical disease presentation.
- Open Access
- 12 August 2022
- Published by Springer Nature in Communications Biology
- Vol. 5 (1) , 1-9
PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19
The ongoing COVID-19 pandemic has claimed more than 6 million lives and continues to test the world economy and healthcare systems. To combat this pandemic, the biological research community has shifted efforts to the development of medical countermeasures, including vaccines and therapeutics. However, to date, the only small molecules approved for the treatment of COVID-19 in the United States are the nucleoside analogue Remdesivir and the protease inhibitor Paxlovid, though multiple compounds have received Emergency Use Authorization and many more are currently being tested in human efficacy trials. One such compound, Apilimod, is being considered as a COVID-19 therapeutic in a Phase II efficacy trial. However, at the time of writing, there are no published efficacy data in human trials or animal COVID-19 models. Here we show that, while Apilimod and other PIKfyve inhibitors have potent antiviral activity in various cell lines against multiple human coronaviruses, these compounds worsen disease in a COVID-19 murine model when given prophylactically or therapeutically.
- 12 August 2022
- Published by Springer Nature in Communications Biology
- Vol. 5 (1) , 1-9
Open AccessPIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19
The ongoing COVID-19 pandemic has claimed more than 6 million lives and continues to test the world economy and healthcare systems. To combat this pandemic, the biological research community has shifted efforts to the development of medical countermeasures, including vaccines and therapeutics. However, to date, the only small molecules approved for the treatment of COVID-19 in the United States are the nucleoside analogue Remdesivir and the protease inhibitor Paxlovid, though multiple compounds have received Emergency Use Authorization and many more are currently being tested in human efficacy trials. One such compound, Apilimod, is being considered as a COVID-19 therapeutic in a Phase II efficacy trial. However, at the time of writing, there are no published efficacy data in human trials or animal COVID-19 models. Here we show that, while Apilimod and other PIKfyve inhibitors have potent antiviral activity in various cell lines against multiple human coronaviruses, these compounds worsen disease in a COVID-19 murine model when given prophylactically or therapeutically.
- Open Access
- 13 October 2021
- Published by American Society for Microbiology in Journal of Virology
- Vol. 95 (21) , e0081721
Redondovirus Diversity and Evolution on Global, Individual, and Molecular Scales
Redondoviridae is a recently established family of DNA viruses predominantly found in the human respiratory tract and associated with multiple clinical conditions. In this study, we found high redondovirus prevalence in saliva from urban North American individuals and nonindustrialized African populations in Botswana, Cameroon, Ethiopia, and Tanzania.
- 13 October 2021
- Published by American Society for Microbiology in Journal of Virology
- Vol. 95 (21) , e0081721
Open AccessRedondovirus Diversity and Evolution on Global, Individual, and Molecular Scales
Redondoviridae is a recently established family of DNA viruses predominantly found in the human respiratory tract and associated with multiple clinical conditions. In this study, we found high redondovirus prevalence in saliva from urban North American individuals and nonindustrialized African populations in Botswana, Cameroon, Ethiopia, and Tanzania.
- Open Access
- 31 August 2021
- Published by American Society for Microbiology in mBio
- Vol. 12 (4)
Signatures of COVID-19 Severity and Immune Response in the Respiratory Tract Microbiome
Rationale Viral infection of the respiratory tract can be associated with propagating effects on the airway microbiome, and microbiome dysbiosis may influence viral disease. Objective To define the respiratory tract microbiome in COVID-19 and relationship disease severity, systemic immunologic features, and outcomes. Methods and Measurements We examined 507 oropharyngeal, nasopharyngeal and endotracheal samples from 83 hospitalized COVID-19 patients, along with non-COVID patients and healthy controls. Bacterial communities were interrogated using 16S rRNA gene sequencing, commensal DNA viruses Anelloviridae and Redondoviridae were quantified by qPCR, and immune features were characterized by lymphocyte/neutrophil (L/N) ratios and deep immune profiling of peripheral blood mononuclear cells (PBMC). Main Results COVID-19 patients had upper respiratory microbiome dysbiosis, and greater change over time than critically ill patients without COVID-19. Diversity at the first time point correlated inversely with disease severity during hospitalization, and microbiome composition was associated with L/N ratios and PBMC profiles in blood. Intubated patients showed patient-specific and dynamic lung microbiome communities, with prominence of Staphylococcus. Anelloviridae and Redondoviridae showed more frequent colonization and higher titers in severe disease. Machine learning analysis demonstrated that integrated features of the microbiome at early sampling points had high power to discriminate ultimate level of COVID-19 severity. Conclusions The respiratory tract microbiome and commensal virome are disturbed in COVID-19, correlate with systemic immune parameters, and early microbiome features discriminate disease severity. Future studies should address clinical consequences of airway dysbiosis in COVID-19, possible use as biomarkers, and role of bacterial and viral taxa identified here in COVID-19 pathogenesis.
- 31 August 2021
- Published by American Society for Microbiology in mBio
- Vol. 12 (4)
Open AccessSignatures of COVID-19 Severity and Immune Response in the Respiratory Tract Microbiome
Rationale Viral infection of the respiratory tract can be associated with propagating effects on the airway microbiome, and microbiome dysbiosis may influence viral disease. Objective To define the respiratory tract microbiome in COVID-19 and relationship disease severity, systemic immunologic features, and outcomes. Methods and Measurements We examined 507 oropharyngeal, nasopharyngeal and endotracheal samples from 83 hospitalized COVID-19 patients, along with non-COVID patients and healthy controls. Bacterial communities were interrogated using 16S rRNA gene sequencing, commensal DNA viruses Anelloviridae and Redondoviridae were quantified by qPCR, and immune features were characterized by lymphocyte/neutrophil (L/N) ratios and deep immune profiling of peripheral blood mononuclear cells (PBMC). Main Results COVID-19 patients had upper respiratory microbiome dysbiosis, and greater change over time than critically ill patients without COVID-19. Diversity at the first time point correlated inversely with disease severity during hospitalization, and microbiome composition was associated with L/N ratios and PBMC profiles in blood. Intubated patients showed patient-specific and dynamic lung microbiome communities, with prominence of Staphylococcus. Anelloviridae and Redondoviridae showed more frequent colonization and higher titers in severe disease. Machine learning analysis demonstrated that integrated features of the microbiome at early sampling points had high power to discriminate ultimate level of COVID-19 severity. Conclusions The respiratory tract microbiome and commensal virome are disturbed in COVID-19, correlate with systemic immune parameters, and early microbiome features discriminate disease severity. Future studies should address clinical consequences of airway dysbiosis in COVID-19, possible use as biomarkers, and role of bacterial and viral taxa identified here in COVID-19 pathogenesis.
- Open Access
- 6 May 2021
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 10 (18)
Rengasvirus, a Circular Replication-Associated Protein-Encoding Single-Stranded DNA Virus-Related Genome That Is a Common Contaminant in Metagenomic Data
We report the genome of a circular Rep-encoding segmented or satellite virus, which we have provisionally named rengasvirus. In metagenomic studies of virus-enriched fractions, rengasvirus was detected widely, including in reagent-negative controls. We thus report this genome to help others recognize a probable contaminating sequence.
- 6 May 2021
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 10 (18)
Open AccessRengasvirus, a Circular Replication-Associated Protein-Encoding Single-Stranded DNA Virus-Related Genome That Is a Common Contaminant in Metagenomic Data
We report the genome of a circular Rep-encoding segmented or satellite virus, which we have provisionally named rengasvirus. In metagenomic studies of virus-enriched fractions, rengasvirus was detected widely, including in reagent-negative controls. We thus report this genome to help others recognize a probable contaminating sequence.
- Open Access
Signatures of COVID-19 severity and immune response in the respiratory tract microbiome
Rationale: Viral infection of the respiratory tract can be associated with propagating effects on the airway microbiome, and microbiome dysbiosis may influence viral disease. Objective: To define the respiratory tract microbiome in COVID-19 and relationship disease severity, systemic immunologic features, and outcomes. Methods and Measurements: We examined 507 oropharyngeal, nasopharyngeal and endotracheal samples from 83 hospitalized COVID-19 patients, along with non-COVID patients and healthy controls. Bacterial communities were interrogated using 16S rRNA gene sequencing, commensal DNA viruses Anelloviridae and Redondoviridae were quantified by qPCR, and immune features were characterized by lymphocyte/neutrophil (L/N) ratios and deep immune profiling of peripheral blood mononuclear cells (PBMC). Main Results: COVID-19 patients had upper respiratory microbiome dysbiosis, and greater change over time than critically ill patients without COVID-19. Diversity at the first time point correlated inversely with disease severity during hospitalization, and microbiome composition was associated with L/N ratios and PBMC profiles in blood. Intubated patients showed patient-specific and dynamic lung microbiome communities, with prominence of Staphylococcus . Anelloviridae and Redondoviridae showed more frequent colonization and higher titers in severe disease. Machine learning analysis demonstrated that integrated features of the microbiome at early sampling points had high power to discriminate ultimate level of COVID-19 severity. Conclusions: The respiratory tract microbiome and commensal virome are disturbed in COVID-19, correlate with systemic immune parameters, and early microbiome features discriminate disease severity. Future studies should address clinical consequences of airway dysbiosis in COVID-19, possible use as biomarkers, and role of bacterial and viral taxa identified here in COVID-19 pathogenesis.
Open AccessSignatures of COVID-19 severity and immune response in the respiratory tract microbiome
Rationale: Viral infection of the respiratory tract can be associated with propagating effects on the airway microbiome, and microbiome dysbiosis may influence viral disease. Objective: To define the respiratory tract microbiome in COVID-19 and relationship disease severity, systemic immunologic features, and outcomes. Methods and Measurements: We examined 507 oropharyngeal, nasopharyngeal and endotracheal samples from 83 hospitalized COVID-19 patients, along with non-COVID patients and healthy controls. Bacterial communities were interrogated using 16S rRNA gene sequencing, commensal DNA viruses Anelloviridae and Redondoviridae were quantified by qPCR, and immune features were characterized by lymphocyte/neutrophil (L/N) ratios and deep immune profiling of peripheral blood mononuclear cells (PBMC). Main Results: COVID-19 patients had upper respiratory microbiome dysbiosis, and greater change over time than critically ill patients without COVID-19. Diversity at the first time point correlated inversely with disease severity during hospitalization, and microbiome composition was associated with L/N ratios and PBMC profiles in blood. Intubated patients showed patient-specific and dynamic lung microbiome communities, with prominence of Staphylococcus . Anelloviridae and Redondoviridae showed more frequent colonization and higher titers in severe disease. Machine learning analysis demonstrated that integrated features of the microbiome at early sampling points had high power to discriminate ultimate level of COVID-19 severity. Conclusions: The respiratory tract microbiome and commensal virome are disturbed in COVID-19, correlate with systemic immune parameters, and early microbiome features discriminate disease severity. Future studies should address clinical consequences of airway dysbiosis in COVID-19, possible use as biomarkers, and role of bacterial and viral taxa identified here in COVID-19 pathogenesis.